High marks to State Program for the Development of Russian Pharma Industry

Print 07 August 2017
GMP News

The Russian Ministry of Economic Development presented to the Government its consolidated report on the implementation and assessment of effectiveness of the state programs for 2016.

In January-December 2016, the production of medicinal products increased by 23.75% as compared to the similar period of 2015 (in prices of the corresponding years) and amounted to 285.87 billion rubles. The share of Russian-made medicinal products in the total market volume increased from 26.5% in 2015 to 30% in 2016 (in monetary terms). 35 medical devices, including 3 systems for diagnostic investigations, have received marketing authorization and were launched in the Russian market. The Russian enterprises launched manufacturing of an artificial lung ventilation device and innovative materials for the medical industry.

Over the last 5 years of implementing the state program, the pharmaceutical and medical industry attracted the investments in the amount of about 156 billion rubles (private investments and investments from federal budget). In 2016, the investments in research, development, technological innovation and re-equipment of pharmaceutical and medical production facilities (key indicator) amounted to 37.4 billion rubles, which is 14% more than in 2015 (32.8%).

Source

Return